Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer

Gregg S. Wilkinson, Jacques Baillargeon, Yong Fang Kuo, Jean L. Freeman, James Goodwin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: Recent studies have linked the use of intravenous and orally administered bisphosphonates with subsequent development of atrial fibrillation. Patients with cancer who receive intravenous bisphosphonate therapy may be at particular risk for this adverse event because they receive higher doses of these drugs than do patients treated for other indications. We examined the association of intravenous bisphosphonates with atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among older patients with cancer. Patients and Methods: Using Surveillance, Epidemiology, and End Results (SEER) -Medicare - linked data, we identified older (≥ age 65 years) patients with cancer who were treated with intravenous infusions of bisphosphonates between January 1, 1995 and December 31, 2003. We then matched 13,714 bisphosphonate nonusers to 6,857 bisphosphonate users, at a 2:1 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region. Patients were observed until December 31, 2003 or until they lost coverage from Medicare Parts A and B; enrolled in a health maintenance organization; received a diagnosis of atrial fibrillation, any SVT, or stroke; or died. Results: Receipt of intravenous bisphosphonates was modestly associated with an increased risk for atrial fibrillation (hazard ratio [HR] = 1.30; 95% CI, 1.18 to 1.43), all SVT (HR = 1.28; 95% CI, 1.19 to 1.38), and stroke (HR = 1.30; 95% CI, 1.09 to 1.54). The risk for all SVT increased 7% for each increase of five bisphosphonate dose equivalents (HR = 1.07; 95% CI, 1.02 to 1.12). Conclusion: Clinicians who treat patients with cancer who have received intravenous bisphosphonates should be aware of the possible cardiovascular adverse events associated with this treatment.

Original languageEnglish (US)
Pages (from-to)4898-4905
Number of pages8
JournalJournal of Clinical Oncology
Volume28
Issue number33
DOIs
StatePublished - Nov 20 2010

Fingerprint

Diphosphonates
Atrial Fibrillation
Stroke
Supraventricular Tachycardia
Neoplasms
Therapeutics
Medicare Part A
Epidemiology
Medicare Part B
Health Maintenance Organizations
Medicare
Intravenous Infusions
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. / Wilkinson, Gregg S.; Baillargeon, Jacques; Kuo, Yong Fang; Freeman, Jean L.; Goodwin, James.

In: Journal of Clinical Oncology, Vol. 28, No. 33, 20.11.2010, p. 4898-4905.

Research output: Contribution to journalArticle

@article{cdf7779290fc4ce5943f1f01cc392358,
title = "Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer",
abstract = "Purpose: Recent studies have linked the use of intravenous and orally administered bisphosphonates with subsequent development of atrial fibrillation. Patients with cancer who receive intravenous bisphosphonate therapy may be at particular risk for this adverse event because they receive higher doses of these drugs than do patients treated for other indications. We examined the association of intravenous bisphosphonates with atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among older patients with cancer. Patients and Methods: Using Surveillance, Epidemiology, and End Results (SEER) -Medicare - linked data, we identified older (≥ age 65 years) patients with cancer who were treated with intravenous infusions of bisphosphonates between January 1, 1995 and December 31, 2003. We then matched 13,714 bisphosphonate nonusers to 6,857 bisphosphonate users, at a 2:1 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region. Patients were observed until December 31, 2003 or until they lost coverage from Medicare Parts A and B; enrolled in a health maintenance organization; received a diagnosis of atrial fibrillation, any SVT, or stroke; or died. Results: Receipt of intravenous bisphosphonates was modestly associated with an increased risk for atrial fibrillation (hazard ratio [HR] = 1.30; 95{\%} CI, 1.18 to 1.43), all SVT (HR = 1.28; 95{\%} CI, 1.19 to 1.38), and stroke (HR = 1.30; 95{\%} CI, 1.09 to 1.54). The risk for all SVT increased 7{\%} for each increase of five bisphosphonate dose equivalents (HR = 1.07; 95{\%} CI, 1.02 to 1.12). Conclusion: Clinicians who treat patients with cancer who have received intravenous bisphosphonates should be aware of the possible cardiovascular adverse events associated with this treatment.",
author = "Wilkinson, {Gregg S.} and Jacques Baillargeon and Kuo, {Yong Fang} and Freeman, {Jean L.} and James Goodwin",
year = "2010",
month = "11",
day = "20",
doi = "10.1200/JCO.2010.28.7524",
language = "English (US)",
volume = "28",
pages = "4898--4905",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer

AU - Wilkinson, Gregg S.

AU - Baillargeon, Jacques

AU - Kuo, Yong Fang

AU - Freeman, Jean L.

AU - Goodwin, James

PY - 2010/11/20

Y1 - 2010/11/20

N2 - Purpose: Recent studies have linked the use of intravenous and orally administered bisphosphonates with subsequent development of atrial fibrillation. Patients with cancer who receive intravenous bisphosphonate therapy may be at particular risk for this adverse event because they receive higher doses of these drugs than do patients treated for other indications. We examined the association of intravenous bisphosphonates with atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among older patients with cancer. Patients and Methods: Using Surveillance, Epidemiology, and End Results (SEER) -Medicare - linked data, we identified older (≥ age 65 years) patients with cancer who were treated with intravenous infusions of bisphosphonates between January 1, 1995 and December 31, 2003. We then matched 13,714 bisphosphonate nonusers to 6,857 bisphosphonate users, at a 2:1 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region. Patients were observed until December 31, 2003 or until they lost coverage from Medicare Parts A and B; enrolled in a health maintenance organization; received a diagnosis of atrial fibrillation, any SVT, or stroke; or died. Results: Receipt of intravenous bisphosphonates was modestly associated with an increased risk for atrial fibrillation (hazard ratio [HR] = 1.30; 95% CI, 1.18 to 1.43), all SVT (HR = 1.28; 95% CI, 1.19 to 1.38), and stroke (HR = 1.30; 95% CI, 1.09 to 1.54). The risk for all SVT increased 7% for each increase of five bisphosphonate dose equivalents (HR = 1.07; 95% CI, 1.02 to 1.12). Conclusion: Clinicians who treat patients with cancer who have received intravenous bisphosphonates should be aware of the possible cardiovascular adverse events associated with this treatment.

AB - Purpose: Recent studies have linked the use of intravenous and orally administered bisphosphonates with subsequent development of atrial fibrillation. Patients with cancer who receive intravenous bisphosphonate therapy may be at particular risk for this adverse event because they receive higher doses of these drugs than do patients treated for other indications. We examined the association of intravenous bisphosphonates with atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among older patients with cancer. Patients and Methods: Using Surveillance, Epidemiology, and End Results (SEER) -Medicare - linked data, we identified older (≥ age 65 years) patients with cancer who were treated with intravenous infusions of bisphosphonates between January 1, 1995 and December 31, 2003. We then matched 13,714 bisphosphonate nonusers to 6,857 bisphosphonate users, at a 2:1 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region. Patients were observed until December 31, 2003 or until they lost coverage from Medicare Parts A and B; enrolled in a health maintenance organization; received a diagnosis of atrial fibrillation, any SVT, or stroke; or died. Results: Receipt of intravenous bisphosphonates was modestly associated with an increased risk for atrial fibrillation (hazard ratio [HR] = 1.30; 95% CI, 1.18 to 1.43), all SVT (HR = 1.28; 95% CI, 1.19 to 1.38), and stroke (HR = 1.30; 95% CI, 1.09 to 1.54). The risk for all SVT increased 7% for each increase of five bisphosphonate dose equivalents (HR = 1.07; 95% CI, 1.02 to 1.12). Conclusion: Clinicians who treat patients with cancer who have received intravenous bisphosphonates should be aware of the possible cardiovascular adverse events associated with this treatment.

UR - http://www.scopus.com/inward/record.url?scp=78650764111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650764111&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.28.7524

DO - 10.1200/JCO.2010.28.7524

M3 - Article

VL - 28

SP - 4898

EP - 4905

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -